United Therapeutics (UTHR) Cash from Operations (2009 - 2026)

United Therapeutics has disclosed Cash from Operations across 18 years of filings, most recently posting 463300000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 463300000.0, changed 0.46% year-over-year; the trailing twelve-month figure through Mar 2026 was 1563300000.0 (up 10.73% YoY), and the FY2025 annual result was 1561200000.0, up 17.64% from the prior year.
• Cash from Operations came in at 463300000.0 for Q1 2026 at United Therapeutics, up from 346200000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 562100000.0 in Q3 2025 to a low of 106300000.0 in Q2 2023.
• The 5-year median for Cash from Operations is 341200000.0 (2024), against an average of 301888235.29.
• Peak annual rise in Cash from Operations reached 221.49% in 2022, while the deepest fall reached 26.58% in 2022.
• United Therapeutics' Cash from Operations stood at 128200000.0 in 2022, then rose by 17.55% to 150700000.0 in 2023, then soared by 126.41% to 341200000.0 in 2024, then advanced by 1.47% to 346200000.0 in 2025, then soared by 33.82% to 463300000.0 in 2026.
• The last three Cash from Operations figures came in at 463300000.0 (Q1 2026), 346200000.0 (Q4 2025), and 562100000.0 (Q3 2025), per Business Quant data.